Viridian Therapeutics Confirms Veligrotug PDUFA Date, Reports Positive Elegrobart Phase 3 Data, and Strong Cash Position
VRDN is trading near its 52-week low of $11.76 (13% above the low).
Summary
Viridian Therapeutics confirmed a June 30, 2026 PDUFA date for veligrotug, announced positive Phase 3 data for elegrobart in TED, and reported a strong cash position of $762.2 million.
Key Events · Product Development and Regulatory · VRDN
-
Veligrotug PDUFA Date Confirmed
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026, for veligrotug in thyroid eye disease (TED). The company is launch-ready, having completed field team hiring and established commercial supply infrastructure.
-
Positive Elegrobart Phase 3 Data
Elegrobart (VRDN-003) showed positive topline data in both REVEAL-1 and REVEAL-2 Phase 3 clinical trials for active and chronic TED, respectively. Viridian plans to submit a Biologics License Application (BLA) in Q1 2027, aiming for the first subcutaneous autoinjector treatment for TED.
-
Strong Cash Position
The company reported cash, cash equivalents, and short-term investments of $762.2 million as of March 31, 2026, providing significant financial runway for ongoing operations and pipeline development.
-
Pipeline Advancement
Viridian is advancing its TSHR program with an IND submission anticipated in Q4 2026, and its FcRn inhibitor portfolio, with VRDN-006 development plans expected in 2026 and VRDN-008 Phase 1 healthy volunteer data on track for 2H 2026.
Analysis · VRDN · Life Sciences
This 8-K filing, accompanied by a press release, provides a comprehensive update on Viridian Therapeutics' pipeline and financial health. The confirmation of a June 30, 2026 PDUFA target action date for veligrotug, a Breakthrough Therapy Designated drug, signals a critical near-term catalyst for potential market entry. Furthermore, the positive topline data from both Phase 3 trials for elegrobart (REVEAL-1 and REVEAL-2) significantly de-risks the company's second major asset, positioning it as a potential first subcutaneous autoinjector treatment for Thyroid Eye Disease (TED) with a BLA submission anticipated in Q1 2027. While the company reported an increased net loss for Q1 2026, its robust cash position of $762.2 million provides substantial runway to advance its multiple clinical programs and support potential commercial launches.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRDN was trading at $13.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $11.76 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.